Formulation affects the rate of membrane degradation catalyzed by cationic amphiphilic drugs

Industrial and Engineering Chemistry Research

Volumn 47, Issue 3, 2008, Pages 650-655

  Casey, Duncan R ^a   Sebai, Sarra C ^a   Shearman, Gemma C ^a   Ces, Oscar ^a   Law, Robert V ^a   Templer, Richard H ^a   Gee, Antony D ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHILES; DEGRADATION; DRUG PRODUCTS; HYDROLYSIS; PHOSPHOLIPIDS; POSITIVE IONS; PRECIPITATION (CHEMICAL);

CATIONIC AMPHIPHILIC DRUG (CAD); COUNTERION CONDENSATION PROCESS;

BIOLOGICAL MEMBRANES;

AMPHIPHILES; BIOLOGICAL MEMBRANES; DEGRADATION; DRUG PRODUCTS; HYDROLYSIS; PHOSPHOLIPIDS; POSITIVE IONS; PRECIPITATION (CHEMICAL);

EID: 39449106650     PISSN: 08885885     EISSN: None     Source Type: Journal    
DOI: 10.1021/ie071265q     Document Type: Article

References (46)

1. Davson, H.; Danielli, J. F. Permeability of Natural Membranes, 2nd Edition; Macmillan: New York, 1952.
2. Zwolinski, B. J.; Eyring, H.; Reese, C E. Diffusion and Membrane Permeability. I, J. Phys. Chem. 1949, 53 (9), 1426-1453.
3. Collander, R. The Permeability of Plant Protoplasts to Small Molecules. Physiol. Plant. 1949, 2 (4), 300-311.
4. Alvarado, F. Transport of Sugars and Amino Acids in the Intestine: Evidence for a Common Carrier. Science 1966, 151 (3713), 1010-1013.
5. Wright, L. L.; Painter, G. R. Role of desolvation energy in the nonfacilitated membrane permeability of dideoxyribose analogs of thymidine. Mol. Pharmacol. 1992, 41 (5), 957-962.
6. Domin, B. A.; Mahony, W. B.; Koszalka, G. W.; Porter, D. J.; Hajian, G.; Zimmerman, T. P. Membrane permeation characteristics of 5′-modified thymidine analogs. Mol. Pharmacol. 1992, 41 (5), 950-956.
7. Kamp, F.; Kizilbash, N.; Corkey, B. E.; Berggren, P.-O.; Hamilton, J. A. Sulfonylureas Rapidly Cross Phospholipid Bilayer Membranes by a Free-Diffusion Mechanism. Diabetes 2003, 52 (10), 2526-2531.
8. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23 (1-3), 3-25.
9. Kabarowski, J. H. S.; Xu, Y.; Witte, O. N. Lysophosphatidylcholine as a ligand for immunoregulation. Biochem. Pharmacol. 2002, 64 (2), 161-167.
10. Murakami, N.; Yokomizo, T.; Okuno, T.; Shimizu, T. G2A is a Proton-sensing G-protein-coupled Receptor Antagonized by Lysophosphatidylcholine. J. Biol. Chem. 2004, 279 (41), 42484-42491.
11. Qiao, J.; Huang, F.; Naikawadi, R. P.; Kim, K. S.; Said, T.; Lum, H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am. J. Physiol. 2006, 291 (1), L91-L101.
12. Xu, Y. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim. Biophys. Acta 2002, 1552 (1-3), 81-88.
13. Guo, J.; Pavlopoulos, S.; Tian, X.; Lu, D.; Nikas, S. P.; Yang, D. P.; Makriyannis, A. Conformational Study of Lipophilic Ligands in Phospholipid Model Membrane Systems by Solution NMR. J. Med. Chem. 2003, 46 (23), 4838-4846.
14. Tian, X.; Guo, J.; Yao, F.; Yang, D.-P.; Makriyannis, A., The Conformation, Location, and Dynamic Properties of the Endocannabinoid Ligand Anandamide in a Membrane Bilayer. J. Biol. Chem. 2005, 250 (33), 29788-29795.
15. Makriyannis, A.; Tian, X.; Guo, J. How lipophilic cannabinergic ligands reach their receptor sites. Prost. Lip. Med. 2005, 77 (1-4), 210-218.
16. Lullmann, H.; Wehling, M. The binding of drugs to different polar lipids in vitro. Biochem. Pharmacol. 1979, 25 (23), 3409-3415.
17. Baciu, M.; Sebai, S. C.; Ces, O.; Mulet, X.; Clarke, J. A.; Shearman, G. C.; Law, R. V.; Templer, R. H.; Plisson, C.; Parker, C. A.; Gee, A. Degradative transport of cationic amphophilic drugs across phospholipid bilayers. Philos. Trans. R. Soc. London, A 2006, 364 (1847), 2597-2614.
18. Leonenko, Z. V.; Finot, E.; Ma, H.; Dahms, T. E. S.; Cramb, D. T. Investigation of Temperature-Induced Phase Transitions in DOPC and DPPC Phospholipid Bilayers Using Temperature-Controlled Scanning Force Microscopy. Biophys. J. 2004, 56 (6), 3783-3793.
19. Bergstrand, N.; Edwards, K. Aggregate Structure in Dilute Aqueous Dispersions of Phospholipids, Fatty Acids, and Lysophospholipids. Langmuir 2001, 17 (11), 3245-3253.
20. Brentel, I.; Arvidson, G.; Lindblom, G., Phase equilibria of the ternary system l-palmitoyl-sw-glycero-3-phosphocholine/oleic acid/water/studied by NMR. Biochim. Biophys. Acta 1987, 904 (2), 401 -404.
21. 31P-NMR, electron microscopy and permeability studies. Biochim. Biophys. Acta 1981, 649, 211-220.
22. Gullion, T.; Schaeffer, J., Rotational-Echo Double-Resonance NMR. J. Magn. Reson. 1989, 81, 196-200.
23. Seydel, J. K.; Wassermann, O. NMR-Studies on the molecular basis of drug-induced phospholipidosis-n. Interaction between several amphiphilic drugs and phospholipids. Biochem. Pharmacol. 1976, 25 (21), 2357-2364.
24. 2H-NMR as a method for determining the orientation of cannabinoid analogs in membranes. Pharmacol., Biochem. Behav. 1991, 40 (3), 553-557.
25. Berquand, A.; Mingeot-Leclercq, M. P.; Dufrene, Y. F. Real-time imaging of drug-membrane interactions by atomic force microscopy. Biochim. Biophys. Acta 2004, 1664 (2), 198-205.
26. Tyteca, D.; Schanck, A.; Dufrêne, Y. F.; Deleu, M.; Courtoy, P, J.; Tulkens, P. M.; Mingeot-Leclercq, M. P. The Macrolide Antibiotic Azithromycin Interacts with Lipids and Affects Membrane Organization and Fluidity: Studies on Langmuir-Blodgett Monolayers, Liposomes and J774 Macrophages. J. Membr. Biol. 2003, 192 (3), 203-215.
27. Agasosler, A. V.; Tungodden, L. M.; Cejka, D.; Bakstad, E.; Sydnes, L. K.; Holmsen, H. Chorpromazine-induced increase in dipalmitoylphosphatidylserine surface area in monolayers at room temperature. Biochem. Pharmacol. 2001, 61 (7), 817-825.
28. Sessa, G.; Weissmann, G. Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res. 1968, 9 (3), 310-318.
29. Wohnsland, F.; Faller, B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 2001, 44 (6), 923-30.
30. Wall, J.; Ayoub, F.; O'Shea, P. Interactions of macromolecules with the mammalian cell surface. J. Cell Sci 1995, 105 (7), 2673-2682.
31. Cladera, J.; O'Shea, P. Generic techniques for fluorescence measurements of protein-ligand interactions; real-time kinetics & spatial imaging. In Protein-Ligand Interactions; Harding, S. E., Chowdery, B., Eds.; Oxford University Press: Oxford, U.K., 2001; pp 169-200.
32. Attard, G. S.; Templer, R. H.; Smith, W. S.; Hunt, A. N.; Jackowski, S. Modulation of CTP:phosphocholine cytidylyltransferase by membrane curvature elastic stress. Proc Natl. Acad. Sci., U.S.A. 2000, 97 (16), 9032-9036.
33. Bezrukov, S. M. Functional consequences of lipid packing stress. Curr. Opin. Colloid Interface Sci. 2000, 5 (3-4), 237-243.
34. Li, S.; Doyle, P.; Metz, S.; Royce, A. E.; Serajuddin, A. T. M. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. J. Pharm. Sci. 2005, 94 (10), 2224-2231.
35. Li, S.; Wong, S.; Sethia, S.; Almoazen, H.; Joshi, Y. M.; Serajuddin, A. T. M. Investigation of Solubility and Dissolution of a Free Base and Two Different Salt Forms as a Function of pH. Pharm. Res. 2005, 22 (4), 628-635.
36. Kunz, W.; Henle, J.; Ninham, B. W. Zur Lehre von der Wirkung der Salze (about the science of the effect of salts): Franz Hofmeister's historical papers. Curr. Opin. Colloid Interface Sci. 2004, 9 (1-2), 19-37.
37. Gassim, A. E. H.; Girgis, Takla, P.; James, K. C. Polymorphism and possible intramolecular bonding in benperidol. Int. J. Pharm. 1986, 34, 1986.
38. Reed, L. L.; Schaefer, J. P. The Crystal and Molecular Structure of Haloperidol, a Patent Psychotropic Drug. Acta Crystallogr., Sect. B: Struct. Sci. 1973, 29, 1886.
39. Jakobsen, A. F.; Mouritsen, O. G.; Weiss, M. Close-up view of the modifications of fluid membranes due to phospholipase A2. J. Phys.: Condens. Matter 2005,17 (47), S4015.
40. Richieri, G. V.; Kleinfeld, A. M. Continuous Measurement of Phospholipase A2 Activity Using the Fluorescent Probe ADIFAB. Anal. Biochem. 1995, 229 (2), 256-263.
41. Honger, T.; Jorgensen, K.; Stokes, D.; Biltonen, R. L.; Mouritsen, O. G.; Byron, R.; Edward, A. D. [9] Phospholipase A2 activity and physical properties of lipid-bilayer substrates. In Methods Enzymology, Vol. 286; Academic Press: New York, 1997; pp 168-190.
42. Leidy, C.; Linderoth, L.; Andresen, T. L.; Mouritsen, O. G.; Jorgensen, K.; Peters, G. H. Domain-Induced Activation of Human Phospholipase A2 Type IIA: Local versus Global Lipid Composition. Biophys. J. 2006, 90 (9), 3165-3175.
43. Nielsen, L. K.; Risbo, J.; Callisen, T. H.; Bjornholm, T. Lag-burst kinetics in phospholipase A2 hydrolysis of DPPC bilayers visualized by atomic force microscopy. Biochim. Biophys. Acta 1999, 1420 (1-2), 266-271.
44. Hiraoka, M.; Abe, A.; Lu, Y.; Yang, K.; Han, X.; Gross, R. W.; Shayman, J. A. Lysosomal phospholipase A2 and phospholipidosis. Mol. Cell. Biol 2006, 26 (16), 6139-6148.
45. Kubo, M.; Hostetier, K. Y. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase Al. Biochemistry 1985, 24 (23), 6515-6520.
46. von Berlepsch, H.; de Vries, R. Weakly charged lamellar bilayer system: Interplay between thermal undulations and electrostatic repulsion. Eur. Phys. J. E 2000, V1 (2), 141-152.